31 results about "Acquired Immuno-Deficiency Syndrome" patented technology

The invention provides compounds with activity against infectious diseases. The compounds of the invention may inhibit retroviral reverse transcriptases and thus inhibit the replication, of the virus. The compounds of the invention may be useful for treating human patients infected with a human retrovirus, such as human immunodeficiency virus (strains of HIV-l or HIV-2) or human T-cell leukemia virus (HTLV-1 or HTLV-II) which results in acquired immunodeficiency syndrome (AIDS) and / or related diseases. Representative of the invention is a compound of the following formula, with the substituents defined herein:

The retrovirus designated human immunodeficiency virus (HIV), particularly the strains known as HIV type-1 (HIV-I) and type-2 (HIV-2), have been etiologically linked to the immunosuppressive disease known as acquired immunodeficiency syndrome (AIDS). HIV seropositive individuals are initially asymptomatic but typically develop AIDS related complex (ARC) followed by AIDS. Affected individuals exhibit severe immunosuppression which makes them highly susceptible to debilitating and ultimately fatal opportunistic infections. The invention is directed to a novel crystalline form of the RT inhibitor 3-chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydropyridin-3-yl)oxy)benzonitrile used in the treatment HIV infection and AIDS.

The invention discloses an anti-AIDS virus bullatacin patch for external use, which comprises a backing layer, a drug reservoir and an anti-sticking layer; a cotton medicinal non-woven fabrics with good permeability is used as the backing layer, a polymeric gel (an acrylate pressure-sensitive gel) as an adhesive; the patch comprises the prepared liquid of bullatacin, and a silicone-oil anti-sticking polyester film is functioned as an anti-sticking layer. The patch for external use has the advantages that not only the disadvantage of serious harmful and side effects of the existing oral or intravenous antitumor drug are solved, but also the disadvantage of heavy skin irritation and a certain extend of toxicity of traditional patches for external use are overcome, and the economic cost is reduced.

The present application discloses compounds of formula (I) wherein X is ═O, ═S, ═NH, ═NOH and ═NO-Me; A is —C(═O)—, —S(═O)2—, —C(═S)— and P(═O)(R5)—; B is, —O—, —(CH2)3-6—, and O—(CH2)2-5—; D is, —O—, —CR7R8— and —NR9; m is 0-12, n is 0-12, m+n is 1-20; p is 0-4; R1 is opt. sub. heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof. The application also discloses the compound for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT), e.g. inflammatory and tissue repair disorders; dermatosis; autoimmune diseases, Alzheimer's disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, ataxia telengiectasia.

This invention relates to piperidine derivatives of formulae Ia and Ib with substituents as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. More particularly, the present invention relates to 1-oxa-3,8-diaza-spiro[4.5]decan-2-one and 1-oxa-3,9-diaza-spiro[5.5]undecan-2-one compounds and related derivatives, to compositions containing and to uses of such derivatives. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), diseases of the immune system and inflammatory diseases.

Methods of treating patients with human immunodeficiency virus are disclosed. The method includes providing an intradermal dose and an intravenous dose of an aTh1 composition that increases HIV-resistant CD4+ cells in a patient. The instructions include a viral load reduction method and a viral clearance method. This regimen results in a spike in viral load followed by a return to sub-baseline levels of virus and may result in a reduction and / or elimination of potential viral reservoirs. Also included are kits configured to provide intradermal and intravenous doses according to the protocol.

The invention discloses an oral liquid for resisting AIDS, which is prepared from cimicifuga rhizome, Bupleurum root, anemarrhena rhizome, raw astragalus root, root of ballon flower, Chinese angelica root, Clematis chinensis, white atractylodes rhizome, dried orange peel, schisandra fruit, gen-seng, tortoiseshell, cornus officinalis, tortoise shell, ledebouriella root, rhizoma dioscoreae, lilyturf root, and licorice root.

The invention belongs to the technical field of medicaments and relates to a heterophylla and astragalus mongholicus reinvigorating particle as well as a preparation method and application thereof in preparation of a medicament for treating acquired immune deficiency syndrome. The method comprises the following steps of: removing the impurities of 15 Chinese herbal medicines such as heterophylla, astragalus mongholicus, radix ophiopogonis, unprocessed rehmannia root, aspartame, angelica, ligustrum lucidum, wolfberry fruit, schisandra, yam, roasted atractylodes, roasted hawthorn, roasted malt, roasted medicated leaven and licorice, washing the rhizomatic Chinese herbal medicines with running water, and drying at a low temperature. The heterophylla and astragalus mongholicus reinvigorating particle is effective in treatment, has the effects of improving the clinical symptoms of patients, enhancing the immunity of the bodies of the patients, strengthening the treatment effect of an antiviral medicament and reducing the toxic and side effects of the antiviral medicament, improving the quality of life and survival ability of the patients and inhibiting the spread of AIDS (Acquired Immune Deficiency Syndrome). In addition to the treatment effect, the heterophylla and astragalus mongholicus reinvigorating particle has small toxic and side effects, is low in cost and is convenient to take and carry.

The invention discloses a Chinese medicine used for preparing a medicine for treating AIDS, in particular the application of honeysuckle leaves as a medicine for treating AIDS and as health food. The application of the aqueous extract or the alcohol extract of the honeysuckle leaves as the medicine or the food for treating or preventing AIDS has very obvious effect, the aqueous extract or the alcohol extract can increase the food-intake of a patient, enhance the working capacity, and improve the living quality, and has good therapy effect and small side effect. The invention develops a new way for the promotion and the application of the honeysuckle leaves.

The present invention relates to a novel anti-HIV drug and its clinical application. The novel anti-HIV drug of the present invention has the structure shown in the following formula (I). The present invention also includes the compound represented by formula (I) or hydrate, solvate, co-crystal, pharmaceutically acceptable salt, and its preparation method. The pharmaceutical composition of the compound is used in medicine, especially for the treatment of acquired immunodeficiency syndrome. (I).